Clinical Trial

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Post intensive care syndrome (PIC syndrome) is an important problem in modern intensive care strategy. Understanding the mechanisms of PIC syndrome helps prevent it in patients with respiratory, neuromuscular transmission, and cognitive impairments that require prolonged support of vital functions. Significant role in the formation and severity of PIC syndrome is played by the severity of the systemic inflammatory response, which is an individual reaction of the body, and this determines the degree of neurological and psychological deficits. Chronic diseases such as diabetes mellitus, especially in the context of metabolic syndrome, worsen the course of PIC syndrome and delays recovery. Early initiation of rehabilitation measures in the intensive care unit and subsequent expansion of the individual rehabilitation program contributes to the rapid and successful recovery of not only vital functions, but also cognitive, motor and emotional disorders. This shortens the hospital stay of patient and improves their quality of life after discharge.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-11.
Trial Details
NCT Number NCT06735898
Lead Sponsor POLYSAN Scientific & Technological Pharmaceutical Company
Conditions Ischemic Stroke
Enrollment 90 participants
Start Date 2024-03-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-06